乌干达和肯尼亚5岁以下儿童严重贫血出院后管理:每月双氢青蒿素-哌喹疟疾化学预防的多中心、两臂、随机、安慰剂对照、优效性试验研究方案
本研究为在乌干达和肯尼亚疟疾流行区开展的多中心、两臂、随机、安慰剂对照、优效性试验,纳入因严重贫血住院后出院的5岁以下儿童。出院后2周随机给予每月3天双氢青蒿素-哌喹(2、6、10周)或安慰剂,随访26周,评估6个月内全因再入院或死亡复合终点。目标检测25%的发病率下降(从每1000儿童年1152降至864),需每组520例,共1040例。
要点
- 严重贫血住院儿童出院后6个月内再入院或死亡风险高,目前无针对性策略。
- 试验旨在评估3个月每月双氢青蒿素-哌喹化学预防是否优于标准院内治疗。
- 主要复合终点为6个月内全因再入院或死亡,目标检测25%的下降。
核心结论
- 每月双氢青蒿素-哌喹出院后化学预防是否安全且优于标准治疗尚待本试验验证。
研究设计与样本
- 多中心、两臂、安慰剂对照、个体随机、优效性试验,在肯尼亚和乌干达疟疾流行区医院开展。
- 纳入5岁以下因严重贫血住院后出院的儿童,出院后2周随机,每组520例,共1040例。
- 干预组在2、6、10周接受3天双氢青蒿素-哌喹,对照组接受安慰剂,随访26周。
关键数值与推荐
- 目标检测全因再入院或死亡复合终点从每1000儿童年1152降至864,即25%的下降(把握度80%,α=0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children hospitalised with severe anaemia in malaria endemic areas in Africa are at high risk of readmission or death within 6 months post-discharge. Currently, no strategy specifically addresses this period. In Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly treatment courses of artemether-lumefantrine given at discharge and at 1 and 2 months prevented 30% of all-cause readmissions by 6 months post-discharge. Another efficacy trial is needed before a policy of malaria chemoprevention can be considered for the post-discharge management of severe anaemia in children under 5 years of age living in malaria endemic areas. OBJECTIVE: We aim to determine if 3 months of PMC with monthly 3-day treatment courses of dihydroartemisinin-piperaquine is safe and superior to a single 3-day treatment course with artemether-lumefantrine provided as part of standard in-hospital care in reducing all-cause readmissions and deaths (composite primary endpoint) by 6 months in the post-discharge management of children less than 5 years of age admitted with severe anaemia of any or undetermined cause. METHODS/DESIGN: This is a multi-centre, two-arm, placebo-controlled, individually randomised trial in children under 5 years of age recently discharged following management for severe anaemia. Children in both arms will receive standard in-hospital care for severe anaemia and a 3-day course of artemether-lumefantrine at discharge. At 2 weeks after discharge, surviving children will be randomised to receive either 3-day courses of dihydroartemisinin-piperaquine at 2, 6 and 10 weeks or an identical placebo and followed for 26 weeks through passive case detection. The trial will be conducted in hospitals in malaria endemic areas in Kenya and Uganda. The study is designed to detect a 25% reduction in the incidence of all-cause readmissions or death (composite primary outcome) from 1152 to 864 per 1000 child years (power 80%, α = 0.05) and requires 520 children per arm (1040 total children). RESULTS: Participant recruitment started in May 2016 and is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02671175 . Registered on 28 January 2016.
引用
- Kwambai TK, Dhabangi A, Idro R, et al. Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial. Trials. 2018. PMID: 30400934. doi:10.1186/s13063-018-2972-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。